These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11334781)

  • 1. Economic impact of beta blockade in heart failure.
    Gregory D; Udelson JE; Konstam MA
    Am J Med; 2001 May; 110 Suppl 7A():74S-80S. PubMed ID: 11334781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
    Díez Manglano J
    Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic analysis of the treatment of heart failure with beta-blockers].
    Díez-Manglano J
    Med Clin (Barc); 2013 Sep; 141(6):265-70. PubMed ID: 23597957
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
    Levy AR; Briggs AH; Demers C; O'Brien BJ
    Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In heart failure, all beta-blockers are not necessarily equal.
    Tang WH; Militello M; Francis GS
    Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.
    Vera-Llonch M; Menzin J; Richner RE; Oster G
    Ann Pharmacother; 2001; 35(7-8):846-51. PubMed ID: 11485131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic study of carvedilol in heart failure. A cost effectiveness study in France].
    Lévy P; Dubois-Randé JL; Cohen-Solal A; Lévy E
    Arch Mal Coeur Vaiss; 2001 Feb; 94(2):166-70. PubMed ID: 11265558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of bisoprolol for heart failure.
    Varney S
    Eur J Heart Fail; 2001 Jun; 3(3):365-71. PubMed ID: 11378009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
    Stewart S; McMurray JJ; Hebborn A; Coats AJ; Packer M;
    Int J Cardiol; 2005 Apr; 100(1):143-9. PubMed ID: 15820297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
    Barry M
    Ir Med J; 2002 Jun; 95(6):174, 176-7. PubMed ID: 12171265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan.
    Inomata T; Izumi T; Kobayashi M
    Circ J; 2004 Jan; 68(1):35-40. PubMed ID: 14695463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical resource use and costs of congestive heart failure after carvedilol use.
    Najib MM; Goldberg Arnold RJ; Kaniecki DJ; Pettit KG; Roth D; Antell L; Xuan J
    Heart Dis; 2002; 4(2):70-7. PubMed ID: 11975837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
    Stecker EC; Fendrick AM; Knight BP; Aaronson KD
    Am Heart J; 2006 Apr; 151(4):820-8. PubMed ID: 16569541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement claims analysis of outcomes with carvedilol and metoprolol.
    Luzier AB; Antell LA; Chang LL; Xuan J; Roth DA
    Ann Pharmacother; 2002 Mar; 36(3):386-91. PubMed ID: 11895048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
    Eur Heart J; 2001 Jun; 22(12):1021-31. PubMed ID: 11428837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effectiveness of carvedilol in heart failure].
    Kárpáti K; Brodszky V; Farsang C; Jermendy G; Vándorfi G; Zámolyi K; Gulácsi L
    Orv Hetil; 2006 Oct; 147(40):1931-7. PubMed ID: 17111685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.